Rasime Derya Aksoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rasime Derya Aksoy has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Fatma Demet Arslan
Department of Medical Biochemistry, Faculty of Medicine , Bakırçay University , Izmir , Türkiye
3 shared publications Fatma Demet Arslan
Faculty of Medicine, Bakırçay University, Department of Medical Biochemistry, İzmir, Turkey
2 shared publicationsNisel Yılmaz
University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Microbiology, Izmir, Turkey
2 shared publicationsA.ö. Koçyiğit
Tissue Typing Laboratory, Tepecik Education and Research Hospital, Izmir, Turkey; Medical Biology and Genetics Department, Faculty of Medicine, İzmir Katip Celebi University, Izmir, Turkey
1 shared publication- Asuman Birinci
Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye
1 shared publication - Ayhan Donmez
Department of Hematology, Ege University Medical School, İzmir, Turkey
1 shared publication
Latest Publications
- 3 September 2026
- Published by Elsevier in Journal of Immunological Methods
Lipemia and serum index–related interference in Luminex-based anti-HLA antibody detection
- 3 September 2026
- Published by Elsevier in Journal of Immunological Methods
Lipemia and serum index–related interference in Luminex-based anti-HLA antibody detection
- 13 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
Evaluation of Methods and Results Used in Screening and Identification of Anti-HLA Antibodies: A Multicenter Study in Türkiye
Objective: Panel-reactive antibodies (PRA) or anti-human leucocyte antigens (anti-HLAs) are produced by the patient's immune system in response to donors during transplant procedures. Antibodies to HLA are known to develop following blood transfusion, pregnancy, and a history of transplantation. Donor-specific antibodies (DSA) arising in patient serum in response to donor-specific HLA can be detected using the single antigen bead (SAB) test. The objective of this multicentre retrospective study is to analyse the distribution of anti-HLA antibodies in Turkey, mean fluorescence intensity (MFI) values, and to assess the concordance of PRA tests across centres on a national scale. Materials and Methods: The study will include adult patients and their donors who were on the living and cadaveric waiting lists and who underwent PRA screening/identification/SAB tests between 2013-2024. Data on patients' anti-HLA antibodies and demographics will be obtained from 12 tissue typing laboratories. Tests and MFI values will be recorded. The data will undergo rigorous testing for statistical significance using SPSS version 23.0, with a p-value <0.05. Results: This study will reveal the distribution of anti-HLA antibodies across Turkey for the first time, and the effects of sensitization factors will be analysed. The correlation between Class I and II antibody positivity, MFI levels, and demographic data will be evaluated. Discussion: The findings of this study will contribute to advancing laboratory consistency and establishing national test standardisation. It is hypothesized that the obtained data may also provide insights into updating the organ allocation system to include antibody testing. The comparison of PRA tests, SAB methods, and the MFI values will provide a new perspective on laboratory and clinical evaluation. This study aims to enhance the efficacy of patient-donor matching through the identification of shared criteria for pre-transplant immunological risk assessment within the national context. Keywords: MFI, PRA screening/identification, SAB, transplantation
- 13 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
Evaluation of Methods and Results Used in Screening and Identification of Anti-HLA Antibodies: A Multicenter Study in Türkiye
Objective: Panel-reactive antibodies (PRA) or anti-human leucocyte antigens (anti-HLAs) are produced by the patient's immune system in response to donors during transplant procedures. Antibodies to HLA are known to develop following blood transfusion, pregnancy, and a history of transplantation. Donor-specific antibodies (DSA) arising in patient serum in response to donor-specific HLA can be detected using the single antigen bead (SAB) test. The objective of this multicentre retrospective study is to analyse the distribution of anti-HLA antibodies in Turkey, mean fluorescence intensity (MFI) values, and to assess the concordance of PRA tests across centres on a national scale. Materials and Methods: The study will include adult patients and their donors who were on the living and cadaveric waiting lists and who underwent PRA screening/identification/SAB tests between 2013-2024. Data on patients' anti-HLA antibodies and demographics will be obtained from 12 tissue typing laboratories. Tests and MFI values will be recorded. The data will undergo rigorous testing for statistical significance using SPSS version 23.0, with a p-value <0.05. Results: This study will reveal the distribution of anti-HLA antibodies across Turkey for the first time, and the effects of sensitization factors will be analysed. The correlation between Class I and II antibody positivity, MFI levels, and demographic data will be evaluated. Discussion: The findings of this study will contribute to advancing laboratory consistency and establishing national test standardisation. It is hypothesized that the obtained data may also provide insights into updating the organ allocation system to include antibody testing. The comparison of PRA tests, SAB methods, and the MFI values will provide a new perspective on laboratory and clinical evaluation. This study aims to enhance the efficacy of patient-donor matching through the identification of shared criteria for pre-transplant immunological risk assessment within the national context. Keywords: MFI, PRA screening/identification, SAB, transplantation
- Open Access
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Lipemia and Serum Index–Related Interference in Luminex-Based Anti-HLA Antibody Detection
BackgroundLuminex bead-based solid-phase immunoassays (SFIA) are the gold standard for anti–human leukocyte antigen (HLA) antibody detection in transplantation immunology. However, preanalytical interferences may compromise assay validity. Although automated hemolysis, icterus, and lipemia (HIL) indices are routinely used to assess sample quality, their relevance for predicting interference in Luminex-based HLA antibody testing remains unclear.MethodsA total of 1,308 patient samples were retrospectively evaluated using Luminex SFIA. Internal control bead mean fluorescence intensity (MFI) values were assessed according to manufacturer-defined criteria. Samples with control bead deviations were analyzed in relation to automated HIL indices and categorized into four interference profiles based on control bead behavior. Control bead normalization ratios and correlation analyses were performed.ResultsControl bead MFI values outside acceptable ranges were observed in 125 samples (9.7%). After exclusion of 16 samples, 109 were included in the final analysis. Elevated lipemia indices were associated with assay interference in two groups, manifesting as signal amplification or signal quenching. Notably, nearly half of the deviated samples showed marked signal suppression despite normal HIL indices, consistent with silent interference. Another interference profile demonstrated pronounced control bead signal elevation in the absence of abnormal HIL indices, indicating an index-independent matrix effect.ConclusionLipemia represents an underrecognized source of interference in Luminex-based HLA antibody testing. Automated HIL indices alone are insufficient to identify all compromised samples. Systematic monitoring of internal control bead values may improve detection of silent and index-independent interferences and enhance analytical accuracy.
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLipemia and Serum Index–Related Interference in Luminex-Based Anti-HLA Antibody Detection
BackgroundLuminex bead-based solid-phase immunoassays (SFIA) are the gold standard for anti–human leukocyte antigen (HLA) antibody detection in transplantation immunology. However, preanalytical interferences may compromise assay validity. Although automated hemolysis, icterus, and lipemia (HIL) indices are routinely used to assess sample quality, their relevance for predicting interference in Luminex-based HLA antibody testing remains unclear.MethodsA total of 1,308 patient samples were retrospectively evaluated using Luminex SFIA. Internal control bead mean fluorescence intensity (MFI) values were assessed according to manufacturer-defined criteria. Samples with control bead deviations were analyzed in relation to automated HIL indices and categorized into four interference profiles based on control bead behavior. Control bead normalization ratios and correlation analyses were performed.ResultsControl bead MFI values outside acceptable ranges were observed in 125 samples (9.7%). After exclusion of 16 samples, 109 were included in the final analysis. Elevated lipemia indices were associated with assay interference in two groups, manifesting as signal amplification or signal quenching. Notably, nearly half of the deviated samples showed marked signal suppression despite normal HIL indices, consistent with silent interference. Another interference profile demonstrated pronounced control bead signal elevation in the absence of abnormal HIL indices, indicating an index-independent matrix effect.ConclusionLipemia represents an underrecognized source of interference in Luminex-based HLA antibody testing. Automated HIL indices alone are insufficient to identify all compromised samples. Systematic monitoring of internal control bead values may improve detection of silent and index-independent interferences and enhance analytical accuracy.
- 20 October 2023
- Published by Elsevier in Journal of Immunological Methods
- Vol. 523, 113577
Assessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodies
- 20 October 2023
- Published by Elsevier in Journal of Immunological Methods
- Vol. 523, 113577
Assessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodies
- Open Access
- 17 August 2023
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 10 (8) , 539-545
Frequencies of HLA Alleles in Patients with Acute Lymphoblastic and Myeloid Leukemia
Objective: Our objective was to investigate the potential correlation between human leukocyte antigens (HLA) - specifically, HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes - and patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Material and Methods: We conducted an analysis of HLA allele frequencies among 393 patients with ALL, 431 patients with AML, and a control group comprising 564 healthy donors. Additionally, we explored the variation in HLA allele distribution between pediatric and adult patients diagnosed with ALL. Results: In comparison to the donor group, a heightened frequency of HLA-A*32 antigen was observed in AML patients (p=0.015, OR: 1.682). Conversely, the frequencies of HLA-B*55 (p=0.027, OR: 0.545) in ALL patients, HLA-B*14 (p=0.023, OR: 0.397), and HLA-B*55 (p=0.04, OR: 0.604) in AML patients were notably diminished. Notably, there were no discernible differences in HLA Class II allele frequency and analysis between the patient and control groups. Moreover, a significant distinction in the frequencies of HLA-A*25 (p=0.019, OR: 8.426) and DRB1*04 (p=0.049, OR: 1.491) was identified between pediatric patients (n=165) and adult patients (n=228) with ALL. Conclusion: The findings indicate that HLA-A*32 might serve as a genetic predisposing factor for AML, and HLA-A*25 and DRB1*04 could be potential genetic risk factors for pediatric ALL patients. Conversely, HLA-B*55 appears to be a potential protective factor against both forms of acute leukemia.
- 17 August 2023
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 10 (8) , 539-545
Open AccessFrequencies of HLA Alleles in Patients with Acute Lymphoblastic and Myeloid Leukemia
Objective: Our objective was to investigate the potential correlation between human leukocyte antigens (HLA) - specifically, HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes - and patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Material and Methods: We conducted an analysis of HLA allele frequencies among 393 patients with ALL, 431 patients with AML, and a control group comprising 564 healthy donors. Additionally, we explored the variation in HLA allele distribution between pediatric and adult patients diagnosed with ALL. Results: In comparison to the donor group, a heightened frequency of HLA-A*32 antigen was observed in AML patients (p=0.015, OR: 1.682). Conversely, the frequencies of HLA-B*55 (p=0.027, OR: 0.545) in ALL patients, HLA-B*14 (p=0.023, OR: 0.397), and HLA-B*55 (p=0.04, OR: 0.604) in AML patients were notably diminished. Notably, there were no discernible differences in HLA Class II allele frequency and analysis between the patient and control groups. Moreover, a significant distinction in the frequencies of HLA-A*25 (p=0.019, OR: 8.426) and DRB1*04 (p=0.049, OR: 1.491) was identified between pediatric patients (n=165) and adult patients (n=228) with ALL. Conclusion: The findings indicate that HLA-A*32 might serve as a genetic predisposing factor for AML, and HLA-A*25 and DRB1*04 could be potential genetic risk factors for pediatric ALL patients. Conversely, HLA-B*55 appears to be a potential protective factor against both forms of acute leukemia.
- 1 February 2022
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 82 (2) , 108-114
Could presepsin be an alternative marker in the early diagnosis of sepsis in COVID-19?
In critical patients with Coronavirus Disease (COVID-19), we investigated the diagnostic value of presepsin in the early diagnosis of superinfection with sepsis, and the effect of antibiotic treatment (AT) in the levels of presepsin and procalcitonin and C-reactive protein. A total of 68 critical patients with sepsis and septic shock in the intensive care unit and 20 outpatients (control group) with COVID-19 were taken. ICU patients (n = 68) were further divided into three groups. C(−)AT(−) had negative blood or tracheal aspirate cultures (C) and not AT on admission to ICU (n = 18), C(−)AT(+) had negative C and AT on admission to intensive care unit (n = 31) and C(+) had positive C (n = 19). Presepsin, procalcitonin, C-reactive protein results were compared between the groups. There were no significant relationships between presepsin levels with sepsis, septic shock, mortality, or length of stay in ICU in patients with COVID-19. For procalcitonin and C-reactive protein levels in C(−)AT(+) and C(+) groups were significantly higher than in control and C(−)AT(−) groups (p < .001). C-reactive protein levels in C(−)AT(−) group were significantly higher than in the control group (p < .001). PCT and CRP, there was no difference between C(−)AT(+) and C(+) groups, and procalcitonin there was no difference between control and C(−)AT(−) groups. Presepsin was not found as a useful biomarker for the prediction of sepsis in COVID-19 patients. These study findings indicate that procalcitonin and C-reactive protein may be an indicator of an early diagnostic marker for superinfection in critical COVID-19 patients.
- 1 February 2022
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 82 (2) , 108-114
Could presepsin be an alternative marker in the early diagnosis of sepsis in COVID-19?
In critical patients with Coronavirus Disease (COVID-19), we investigated the diagnostic value of presepsin in the early diagnosis of superinfection with sepsis, and the effect of antibiotic treatment (AT) in the levels of presepsin and procalcitonin and C-reactive protein. A total of 68 critical patients with sepsis and septic shock in the intensive care unit and 20 outpatients (control group) with COVID-19 were taken. ICU patients (n = 68) were further divided into three groups. C(−)AT(−) had negative blood or tracheal aspirate cultures (C) and not AT on admission to ICU (n = 18), C(−)AT(+) had negative C and AT on admission to intensive care unit (n = 31) and C(+) had positive C (n = 19). Presepsin, procalcitonin, C-reactive protein results were compared between the groups. There were no significant relationships between presepsin levels with sepsis, septic shock, mortality, or length of stay in ICU in patients with COVID-19. For procalcitonin and C-reactive protein levels in C(−)AT(+) and C(+) groups were significantly higher than in control and C(−)AT(−) groups (p < .001). C-reactive protein levels in C(−)AT(−) group were significantly higher than in the control group (p < .001). PCT and CRP, there was no difference between C(−)AT(+) and C(+) groups, and procalcitonin there was no difference between control and C(−)AT(−) groups. Presepsin was not found as a useful biomarker for the prediction of sepsis in COVID-19 patients. These study findings indicate that procalcitonin and C-reactive protein may be an indicator of an early diagnostic marker for superinfection in critical COVID-19 patients.
- 1 May 2019
- Published by Elsevier in Transplantation Proceedings
- Vol. 51 (4) , 1016-1020
Comparison of Single Antigen Bead–Based, Cell-Based, and Solid Phase–Based Crossmatch Methods
- 1 May 2019
- Published by Elsevier in Transplantation Proceedings
- Vol. 51 (4) , 1016-1020
Comparison of Single Antigen Bead–Based, Cell-Based, and Solid Phase–Based Crossmatch Methods
- Open Access
- 5 September 2013
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 30 (3) , 331-332
β-Thalassemia Mutation At Codon 37 (TGG>>TGA) Detected In A Turkish Family
- 5 September 2013
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 30 (3) , 331-332
Open Accessβ-Thalassemia Mutation At Codon 37 (TGG>>TGA) Detected In A Turkish Family